SEARCH

SEARCH BY CITATION

References

  • 1
    Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 66675.
  • 2
    Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? Int J Oncol 2004; 25: 48791.
  • 3
    Khong HT, Restifo NP. Natural selection of tumor variants in the generation of ‘tumor escape’ phenotypes. Nat Immunol 2002; 3: 9991005.
  • 4
    Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 74554.
  • 5
    Watson NF, Ramage JM, Madjd Z et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006; 118: 610.
  • 6
    Kikuchi E, Yamazaki K, Torigoe T et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007; 98: 142430.
  • 7
    Vitale M, Pelusi G, Taroni B et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005; 11: 6772.
  • 8
    Sato N, Hirohashi Y, Tsukahara T et al. Molecular pathological approaches to human tumor immunology. Pathol Int 2009; 59: 20517.
  • 9
    Kitamura H, Torigoe T, Honma I et al. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of Bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Cancer Res 2006; 12: 46414.
  • 10
    Tsukahara T, Kawaguchi S, Torigoe T et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 137480.
  • 11
    Whitmore WF Jr. Management of invasive bladder neoplasms. Semin Urol 1983; 1: 3441.
  • 12
    Sobin LH, Wittekind Ch. TNM Classification of Malignant tumors, 5th edn. New York: Wiley-Liss Inc, 1997.
  • 13
    Mostofi FK, Davis CJ, Sesterhenn IA. Histological typing of urinary bladder tumours, 2nd edn. New York: Springer, 1999.
  • 14
    Kitamura H, Torigoe T, Honma I et al. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy. Urology 2006; 67: 9559.
  • 15
    Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immuol 1986; 137: 2299306.
  • 16
    Eryigit M, Kirkali Z. HLA antigens and transitional cell carcinoma of the bladder. Urol Int 1990; 45: 757.
  • 17
    Levin I, Klein T, Goldstein J, Kuperman O, Kanetti J, Klein B. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival. Cancer 1991; 68: 25914.
  • 18
    Witjes JA, Umbas R, Debruyne FM, Schalken JA. Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer. J Urol 1995; 154: 21859.
  • 19
    Kamarashev J, Ferrone S, Seifert B et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001; 95: 238.
  • 20
    Hofbauer GF, Burkhart A, Schüler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother 2004; 27: 738.
  • 21
    Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117: 24855.
  • 22
    Ramnath N, Tan D, Li Q et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2005; 55: 8919.
  • 23
    Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 3217.
  • 24
    Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 2817.